Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07423481
Starting soon Observational

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

NCT07423481 · tracked via the Priya Life Science France tracker
Sponsor
Nantes University Hospital
Phase
Observational
Started
2026-10-01
Last updated
2026-09-18

Condition(s) studied

Obesity & Overweight

Investigational drug(s) / intervention(s)

SEMAFOLLOW questionnaire

SEMAFOLLOW questionnaire: If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

Study summary

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY * No objection to the use of their data * Patients able to complete an online questionnaire (via the internet) Exclusion Criteria: • Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nantes university hospital Nantes France

More Nantes University Hospital trials in France

Inflammatory Bowel Disease Cohort in Nantes Recruiting
Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis Starting soon
Risk Analysis of Intracranial Aneurysm Rupture Through Social Determinants of Health Active, not recruiting
Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma Recruiting
Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies Recruiting

Other trials for the same condition

Childhood Obesity Risk Markers (MARIOBE) Starting soon
Postprandial Thermogenesis in Obese Adolescents: Effect of Weight Loss Starting soon
Dramatherapy for Psychological and Social Well-Being in Obesity and Bariatric Care Recruiting
High-Intensity Interval Training in Low Versus Normal Oxygen: Effects on Body Fat and Gut Health in Adults Aged 50-75 With Overweight or Obesity (HYPOXFAT) Recruiting
SENSILINS: Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07423481 on ClinicalTrials.gov ↗ ← All trials in France